A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Alliance
- 16 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2021.
- 18 Jun 2018 Planned number of patients changed from 132 to 73.
- 18 Jun 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2018.